A Phase 3 interventional study of Cilofexor and Placebo in Primary Sclerosing Cholangitis, sponsored by Gilead Sciences. Terminated at 201 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-29.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.
Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one has the largest enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2019, is one of 4 in phase 3, and was the 47th registered.
150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.
Browse Cholangitis, Sclerosing studies →19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:
Ipsen · Sites in United States, Argentina, Australia and 22 more countries
Ages 18–75
Takeda · Sites in United States
Ages 18–68 · Healthy volunteers
LISCure Biosciences · Sites in United States
Ages 18–75
Mayo Clinic · Sites in United States
Ages 18–75
Elizabeth C. Verna · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 31 · Phase 3 6
First in 1997; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 419 is above the median of 33 across 95 interventional studies indexed under Cholangitis, Sclerosing.
Median enrollment 27 across the 57 interventional studies, 129 across the 18 observational. Of the 48 that completed or were terminated, 25 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 75 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 7 studies filed under Cholangitis, Sclerosing — fewer than ten, so there is no comparison to draw.
4 of the studies in Cholangitis, Sclerosing with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06197308University of MinnesotaEvaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC | 2027-03-31 |
| NCT05295680Aparna GoelOral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis. | 2027-05 |
| NCT05835505Brigham and Women's HospitalDetoxification of the Liver In PSC (Dolphin) | 2027-05-01 |
| NCT05912387Stanford UniversityStatin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Cholangitis, Sclerosing with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
Key Inclusion Criteria:
Individual has the following laboratory parameters at the screening visit, as determined by the central laboratory:
Key Exclusion Criteria:
Current or prior history of any of the following:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received cilofexor 100 mg tablet, orally, once daily for up to 100.3 weeks.
Drug: Cilofexor
Participants received placebo to match cilofexor 100 mg tablet, orally, once daily for up to 98.1 weeks.
Drug: Placebo
Participants who received cilofexor in blinded phase and had entered the open-label extension (OLE) phase received open-label cilofexor 100 mg tablet, orally, once daily for up to 44.7 weeks.
Drug: Cilofexor
Participants who received placebo in blinded phase and had entered the OLE phase received open-label cilofexor 100 mg tablet, orally, once daily for up to 45.0 weeks.
Drug: Cilofexor
100 mg tablet administered orally once daily
Also known as: GS-9674
Tablet administered orally once daily
Percentage of Participants With Progression of Liver Fibrosis at Blinded Phase Week 96
Progression of liver fibrosis was defined as having a ≥ 1-stage increase from baseline in fibrosis according to the Ludwig classification at Blinded Phase Week 96. The stages of fibrosis was assessed according to Ludwig classification. Ludwig classification fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=no fibrosis, 4=cirrhosis).
Time frame: Blinded Phase Week 96
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) in The Blinded Phase
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. For Blinded Study Phase and OLE Phase, TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.
Time frame: First dose date in the Blinded Phase up to 100.3 weeks plus 30 days
Percentage of Participants Who Experienced TEAEs in The OLE Phase
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. For Blinded Study Phase and OLE Phase, TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.
Time frame: First dose date in the OLE Phase up to 45 weeks plus 30 days
Percentage of Participants Who Experienced Treatment-emergent Serious Adverse Events (SAEs) in the Blinded Phase
An SAE was defined as an event that, at any dose, results in the following: death, a life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect or a medically important event or reaction.
Time frame: First dose date in the Blinded Phase up to 100.3 weeks plus 30 days
Percentage of Participants Who Experienced Treatment-emergent SAEs in the OLE Phase
An SAE was defined as an event that, at any dose, results in the following: death, a life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect or a medically important event or reaction.
Time frame: First dose date in the OLE Phase up to 45 weeks plus 30 days
Change From Baseline in Serum Concentrations of Alkaline Phosphatase (ALP) at Blinded Phase Week 96
Time frame: Baseline, Blinded Phase Week 96
Change From Baseline in Serum Concentrations of Alanine Aminotransferase (ALT) at Blinded Phase Week 96
Time frame: Baseline, Blinded Phase Week 96
Change From Baseline in Serum Concentrations of Fasting Total Bile Acids at Blinded Phase Week 96
Time frame: Baseline, Blinded Phase Week 96
Percentage of Participants With ≥ 25% Relative Reduction in Serum ALP Concentration From Baseline and No Worsening of Fibrosis According to the Ludwig Classification at Blinded Phase Week 96
The stages of fibrosis was assessed according to Ludwig classification. Ludwig classification fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=no fibrosis, 4=cirrhosis).The percentage of participants with ≥ 25% reduction in serum ALP Concentration from baseline and no increase in fibrosis according to the Ludwig Classification at Blinded Phase Week 96 was analyzed.
Time frame: Baseline, Blinded Phase Week 96
Percentage of Participants With Fibrosis Improvement According to the Ludwig Classification at Blinded Phase Week 96
Fibrosis improvement was defined as having ≥ 1-stage decrease from baseline in fibrosis according to the Ludwig classification score at Blinded Study Phase Week 96. The stages of fibrosis was assessed according to Ludwig classification. Ludwig classification fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=no fibrosis, 4=cirrhosis).
Time frame: Blinded Phase Week 96
Change From Baseline in Primary Sclerosing Cholangitis (PSC) Symptoms - Module 1 Based on Disease-specific Patient Reported Outcome (PSC-PRO) at Blinded Phase Week 96
The PSC-PRO addressed the severity of common everyday symptoms of PSC (eg, pruritus, fatigue, and right upper quadrant abdominal discomfort); and their functional impact (eg, on physical function, activities of daily living, and work productivity, etc). PSC-PRO module 1 - PSC symptoms contains a total of 12 questions asking about the severity of specific PSC symptoms on a scale of 0 (no symptoms) to 10 (symptoms as bad as you could imagine) with a 24-hour recall period. The total score, which is computed as 12 times the average of nonmissing scores of the 12 questions, can potentially range between 0 and 120, with higher scores indicating more severe symptoms. A positive change from baseline indicates worsening of symptoms.
Time frame: Baseline, Blinded Phase Week 96
Change From Baseline in Enhanced Liver Fibrosis (ELF™ ) Test Score at Blinded Phase Week 96
The Enhanced Liver Fibrosis (ELF™) test is a composite of three serum biomarkers of hepatobiliary fibrosis: hyaluronic acid, procollagen III amino-terminal peptide, and tissue inhibitor of metalloproteinase. A typical range for ELF™ test scores in PSC is between 6 and 14. Higher ELF™ test scores are associated with more severe liver disease. A positive change from baseline indicated worsening of fibrosis.
Time frame: Baseline, Blinded Phase Week 96
Change From Baseline in Liver Stiffness by FibroScan® at Blinded Phase Week 96
Change in liver stiffness was measured by FibroScan® scores. FibroScan measures liver scarring by measuring the stiffness of the liver. It's normally between 2 and 6 kPa. Many people with liver disease(s) have a result that's higher than the normal range. Higher scores indicate increased scarring of the liver. A positive change from baseline indicates severe liver disease(s).
Time frame: Baseline, Blinded Phase Week 96
Participants were enrolled at study sites in Europe, North America, Oceania, and Asia.
| Milestone | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) | Cilofexor From Cilofexor 100 mg (OLE Phase) | Cilofexor From Placebo (OLE Phase) |
|---|---|---|---|---|
| Started | 278 | 141 | 0 | 0 |
| Completed | 123 | 66 | 0 | 0 |
| Not completed | 155 | 75 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 119 | 57 | 0 | 0 |
| Withdrew: Adverse event | 17 | 7 | 0 | 0 |
| Withdrew: Withdrew consent | 12 | 4 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 1 | 0 | 0 |
| Withdrew: Investigator's discretion | 1 | 2 | 0 | 0 |
| Withdrew: Randomized but never treated | 1 | 2 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 |
| Milestone | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) | Cilofexor From Cilofexor 100 mg (OLE Phase) | Cilofexor From Placebo (OLE Phase) |
|---|---|---|---|---|
| Started | 0 | 0 | 80 | 45 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 80 | 45 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 76 | 42 |
| Withdrew: Adverse event | 0 | 0 | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 |
| Withdrew: Withdrew consent | 0 | 0 | 1 | 0 |
Progression of liver fibrosis was defined as having a ≥ 1-stage increase from baseline in fibrosis according to the Ludwig classification at Blinded Phase Week 96. The stages of fibrosis was assessed according to Ludwig classification. Ludwig classification fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=no fibrosis, 4=cirrhosis).
| percentage of participants | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) |
|---|---|---|
| Percentage of Participants With Progression of Liver Fibrosis at Blinded Phase Week 96 | 30.8 | 32.8 |
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. For Blinded Study Phase and OLE Phase, TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.
| percentage of participants | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) |
|---|---|---|
| Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) in The Blinded Phase | 97.1 | 95.0 |
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. For Blinded Study Phase and OLE Phase, TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.
| percentage of participants | Cilofexor From Cilofexor 100 mg (OLE Phase) | Cilofexor From Placebo (OLE Phase) |
|---|---|---|
| Percentage of Participants Who Experienced TEAEs in The OLE Phase | 66.3 | 73.3 |
An SAE was defined as an event that, at any dose, results in the following: death, a life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect or a medically important event or reaction.
| percentage of participants | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) |
|---|---|---|
| Percentage of Participants Who Experienced Treatment-emergent Serious Adverse Events (SAEs) in the Blinded Phase | 19.1 | 18.7 |
An SAE was defined as an event that, at any dose, results in the following: death, a life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect or a medically important event or reaction.
| percentage of participants | Cilofexor From Cilofexor 100 mg (OLE Phase) | Cilofexor From Placebo (OLE Phase) |
|---|---|---|
| Percentage of Participants Who Experienced Treatment-emergent SAEs in the OLE Phase | 11.3 | 2.2 |
| units per liter (U/L) | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) |
|---|---|---|
| Change From Baseline in Serum Concentrations of Alkaline Phosphatase (ALP) at Blinded Phase Week 96 | 0 (-17 to 16) | 3 (-19 to 25) |
| U/L | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) |
|---|---|---|
| Change From Baseline in Serum Concentrations of Alanine Aminotransferase (ALT) at Blinded Phase Week 96 | -13 (-20 to -6) | -3 (-12 to 6) |
| micromoles per liter (μmol/L) | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) |
|---|---|---|
| Change From Baseline in Serum Concentrations of Fasting Total Bile Acids at Blinded Phase Week 96 | 7.2 (0.9 to 13.5) | 9.8 (1.8 to 17.9) |
The stages of fibrosis was assessed according to Ludwig classification. Ludwig classification fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=no fibrosis, 4=cirrhosis).The percentage of participants with ≥ 25% reduction in serum ALP Concentration from baseline and no increase in fibrosis according to the Ludwig Classification at Blinded Phase Week 96 was analyzed.
| percentage of participants | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) |
|---|---|---|
| Percentage of Participants With ≥ 25% Relative Reduction in Serum ALP Concentration From Baseline and No Worsening of Fibrosis According to the Ludwig Classification at Blinded Phase Week 96 | 9.8 | 6.6 |
Fibrosis improvement was defined as having ≥ 1-stage decrease from baseline in fibrosis according to the Ludwig classification score at Blinded Study Phase Week 96. The stages of fibrosis was assessed according to Ludwig classification. Ludwig classification fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=no fibrosis, 4=cirrhosis).
| percentage of participants | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) |
|---|---|---|
| Percentage of Participants With Fibrosis Improvement According to the Ludwig Classification at Blinded Phase Week 96 | 25.6 | 17.2 |
The PSC-PRO addressed the severity of common everyday symptoms of PSC (eg, pruritus, fatigue, and right upper quadrant abdominal discomfort); and their functional impact (eg, on physical function, activities of daily living, and work productivity, etc). PSC-PRO module 1 - PSC symptoms contains a total of 12 questions asking about the severity of specific PSC symptoms on a scale of 0 (no symptoms) to 10 (symptoms as bad as you could imagine) with a 24-hour recall period. The total score, which is computed as 12 times the average of nonmissing scores of the 12 questions, can potentially range between 0 and 120, with higher scores indicating more severe symptoms. A positive change from baseline indicates worsening of symptoms.
| score on a scale | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) |
|---|---|---|
| Baseline | 11 ± 11.0 | 11 ± 11.8 |
| Change at Blinded Phase Week 96 | 1 ± 9.0 | 0 ± 6.8 |
The Enhanced Liver Fibrosis (ELF™) test is a composite of three serum biomarkers of hepatobiliary fibrosis: hyaluronic acid, procollagen III amino-terminal peptide, and tissue inhibitor of metalloproteinase. A typical range for ELF™ test scores in PSC is between 6 and 14. Higher ELF™ test scores are associated with more severe liver disease. A positive change from baseline indicated worsening of fibrosis.
| score on a scale | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) |
|---|---|---|
| Change From Baseline in Enhanced Liver Fibrosis (ELF™ ) Test Score at Blinded Phase Week 96 | 0.27 (0.16 to 0.38) | 0.30 (0.15 to 0.45) |
Change in liver stiffness was measured by FibroScan® scores. FibroScan measures liver scarring by measuring the stiffness of the liver. It's normally between 2 and 6 kPa. Many people with liver disease(s) have a result that's higher than the normal range. Higher scores indicate increased scarring of the liver. A positive change from baseline indicates severe liver disease(s).
| kilopascals (kPa) | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) |
|---|---|---|
| Change From Baseline in Liver Stiffness by FibroScan® at Blinded Phase Week 96 | 2.4 (1.2 to 3.6) | 2.8 (1.1 to 4.4) |
Collected over All-cause mortality: Randomization up to 3.4 years; Adverse events: Blinded Phase: First dose date in the Blinded Phase up to 100.3 weeks plus 30 days; Open-Label Extension (OLE) Phase: First dose date in the OLE Phase up to 45 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cilofexor 100 mg (Blinded Phase) | 2/278 (0.7%) | 53/277 (19.1%) | 232/277 (83.8%) |
| Placebo (Blinded Phase) | 0/141 (0%) | 26/139 (18.7%) | 109/139 (78.4%) |
| Cilofexor From Cilofexor 100 mg (OLE Phase) | 0/80 (0%) | 9/80 (11.3%) | 34/80 (42.5%) |
| Cilofexor From Placebo (OLE Phase) | 0/45 (0%) | 1/45 (2.2%) | 24/45 (53.3%) |
| Event | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) | Cilofexor From Cilofexor 100 mg (OLE Phase) | Cilofexor From Placebo (OLE Phase) |
|---|---|---|---|---|
| CholangitisHepatobiliary disorders | 10/277 | 7/139 | 2/80 | 1/45 |
| PyrexiaGeneral disorders | 4/277 | 1/139 | 0/80 | 0/45 |
| Cholangitis acuteHepatobiliary disorders | 4/277 | 0/139 | 0/80 | 0/45 |
| Cholecystitis acuteHepatobiliary disorders | 4/277 | 0/139 | 0/80 | 0/45 |
| Bile duct stenosisHepatobiliary disorders | 1/277 | 2/139 | 0/80 | 0/45 |
| CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/277 | 2/139 | 0/80 | 0/45 |
| Abdominal painGastrointestinal disorders | 3/277 | 0/139 | 1/80 | 0/45 |
| Abdominal pain upperGastrointestinal disorders | 2/277 | 0/139 | 1/80 | 0/45 |
| Obstructive pancreatitisGastrointestinal disorders | 0/277 | 0/139 | 1/80 | 0/45 |
| GastroenteritisInfections and infestations | 0/277 | 0/139 | 1/80 | 0/45 |
| Event | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) | Cilofexor From Cilofexor 100 mg (OLE Phase) | Cilofexor From Placebo (OLE Phase) |
|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 135/277 | 50/139 | 14/80 | 11/45 |
| Covid-19Infections and infestations | 65/277 | 26/139 | 11/80 | 11/45 |
| FatigueGeneral disorders | 34/277 | 24/139 | 3/80 | 0/45 |
| Abdominal pain upperGastrointestinal disorders | 40/277 | 20/139 | 1/80 | 2/45 |
| Abdominal painGastrointestinal disorders | 38/277 | 17/139 | 1/80 | 0/45 |
| HeadacheNervous system disorders | 32/277 | 18/139 | 1/80 | 0/45 |
| NauseaGastrointestinal disorders | 34/277 | 16/139 | 4/80 | 0/45 |
| PyrexiaGeneral disorders | 33/277 | 9/139 | 3/80 | 2/45 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 15/277 | 14/139 | 2/80 | 0/45 |
| NasopharyngitisInfections and infestations | 15/277 | 12/139 | 0/80 | 1/45 |
Safety Analysis Set included all participants who took at least 1 dose of study drug.
| Age, Categorical(Participants) | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) | Total |
|---|---|---|---|
| <=18 years | 1 | 0 | 1 |
| Between 18 and 65 years | 258 | 133 | 391 |
| >=65 years | 18 | 6 | 24 |
| Age, Continuous(years) | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) | Total |
|---|---|---|---|
| Mean | 43 ± 13.1 | 44 ± 12.8 | 44 ± 13.0 |
| Sex: Female, Male(Participants) | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) | Total |
|---|---|---|---|
| Female | 107 | 52 | 159 |
| Male | 170 | 87 | 257 |
| Ethnicity (NIH/OMB)(Participants) | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 3 | 14 |
| Not Hispanic or Latino | 258 | 130 | 388 |
| Unknown or Not Reported | 8 | 6 | 14 |
| Race/Ethnicity, Customized(Participants) | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) | Total |
|---|---|---|---|
| Race — White | 228 | 117 | 345 |
| Race — Asian | 28 | 10 | 38 |
| Race — Black or African American | 10 | 7 | 17 |
| Race — Unknown or Not Reported | 6 | 5 | 11 |
| Race — Other or More Than One Race | 5 | 0 | 5 |
| Region of Enrollment(Participants) | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) | Total |
|---|---|---|---|
| United States | 114 | 57 | 171 |
| Japan | 19 | 8 | 27 |
| United Kingdom | 11 | 8 | 19 |
| Switzerland | 2 | 4 | 6 |
| Spain | 13 | 3 | 16 |
| New Zealand | 4 | 2 | 6 |
| Canada | 28 | 10 | 38 |
| Austria | 3 | 1 | 4 |
| Belgium | 4 | 2 | 6 |
| Finland | 11 | 8 | 19 |
| Denmark | 4 | 3 | 7 |
| Italy | 17 | 6 | 23 |
| Israel | 8 | 3 | 11 |
| Australia | 18 | 13 | 31 |
| France | 8 | 6 | 14 |
| Germany | 13 | 5 | 18 |
| Alkaline Phosphatase (ALP)(units per liter (U/L)) | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) | Total |
|---|---|---|---|
| Mean | 223 ± 177.7 | 243 ± 189.5 | 230 ± 181.7 |
| Aspartate Aminotransferase (AST)(U/L) | Cilofexor 100 mg (Blinded Phase) | Placebo (Blinded Phase) | Total |
|---|---|---|---|
| Mean | 49 ± 34.1 | 51 ± 34.6 | 50 ± 34.2 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 201 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Nov 2022, 43 months.
Results were first posted in Nov 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilofexor